The U.S. Food and Drug Administration issued formal warnings to ImmunityBio and publicly criticized statements by Patrick Soon‑Shiong after television ads and a podcast implied the company’s intravesical therapy Anktiva cured or prevented wide swaths of cancer. The FDA said the materials omitted required risk information, overstated efficacy, and misstated that patients would be "cancer free," violations that prompted a warning letter and rare public rebuke. STAT and other outlets reported the FDA characterized some claims as “false and misleading,” and regulators noted combination‑use requirements for Anktiva were not disclosed. The action underlines increased scrutiny of promotional claims in broadcast and digital channels and could affect ImmunityBio’s marketing and investor communications.